Literature DB >> 12734338

Differential roles of CB1 and CB2 cannabinoid receptors in mast cells.

Maria-Teresa Samson1, Andrea Small-Howard, Lori M N Shimoda, Murielle Koblan-Huberson, Alexander J Stokes, Helen Turner.   

Abstract

Cannabinoid modulation of immune responses is a pathological consequence of marijuana abuse and a potential outcome of therapeutic application of the drug. Moreover, endogenous cannabinoids are physiological immune regulators. In the present report, we describe alterations in gene transcription that occur after cannabinoid exposure in a mast cell line, RBL2H3. Cannabinoid exposure causes marked changes in the transcript levels for numerous genes, acting both independently of and in concert with immunoreceptor stimulation via Fc epsilon RI. In two mast cell lines, we observed mRNA and protein expression corresponding to both CB1 and CB2 cannabinoid receptor isoforms, contrary to the prevailing view that CB1 is restricted to the CNS. We show that coexpression of the two isoforms is not functionally redundant in mast cells. Analysis of signaling pathways downstream of cannabinoid application reveals that activation of extracellular signal-regulated kinase, AKT, and a selected subset of AKT targets is accomplished by CB2 ligands and nonselective CB1/CB2 agonists in mast cells. CB1 inhibition does not affect AKT or extracellular signal-regulated kinase activation by cannabinoids, indicating that CB2 is the predominant regulatory receptor for these kinases in this cell context. CB1 receptors are, however, functional in these mast cells, since they can contribute to suppression of secretory responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734338     DOI: 10.4049/jimmunol.170.10.4953

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  Cannabinoids cool the intestine.

Authors:  George Kunos; Pál Pacher
Journal:  Nat Med       Date:  2004-07       Impact factor: 53.440

2.  CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents.

Authors:  Catherine Lombard; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Clin Immunol       Date:  2006-12-20       Impact factor: 3.969

Review 3.  Complementary Therapies in Inflammatory Bowel Diseases.

Authors:  Henit Yanai; Nir Salomon; Adi Lahat
Journal:  Curr Gastroenterol Rep       Date:  2016-12

Review 4.  Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches.

Authors:  Abigail R Basson; Minh Lam; Fabio Cominelli
Journal:  Gastroenterol Clin North Am       Date:  2017-12       Impact factor: 3.806

Review 5.  Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists.

Authors:  William E Greineisen; Helen Turner
Journal:  Int Immunopharmacol       Date:  2010-02-25       Impact factor: 4.932

Review 6.  Human eosinophils and mast cells: Birds of a feather flock together.

Authors:  Piper A Robida; Pier Giorgio Puzzovio; Hadas Pahima; Francesca Levi-Schaffer; Bruce S Bochner
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

7.  Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis.

Authors:  Udai P Singh; Narendra P Singh; Balwan Singh; Robert L Price; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Toxicol Appl Pharmacol       Date:  2011-11-18       Impact factor: 4.219

Review 8.  The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract.

Authors:  Federico Massa; Martin Storr; Beat Lutz
Journal:  J Mol Med (Berl)       Date:  2005-08-26       Impact factor: 4.599

Review 9.  An overview on the biochemistry of the cannabinoid system.

Authors:  María Gómez-Ruiz; Mariluz Hernández; Rosario de Miguel; Jose A Ramos
Journal:  Mol Neurobiol       Date:  2007-06-30       Impact factor: 5.590

10.  Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation.

Authors:  Carl Potenzieri; Thaddeus S Brink; Cholawat Pacharinsak; Donald A Simone
Journal:  J Neurophysiol       Date:  2008-09-10       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.